Synthekine has reported positive initial data from a Phase Ia/Ib trial evaluating STK-012 in first-line, programmed ...

According to one of the authors, additional work is needed to validate findings in a larger prospective study ‘and to apply ...

AstraZeneca has dropped the lead candidate from its $200 million buyout of Neogene Therapeutics as part of a wider cell therapy clearout. When AstraZeneca scooped up the company back in 2022, ...

-- STK-012 is an <ALPHA>/<BETA> biased IL-2 designed to specifically stimulate antigen activated T cells -- Results from an ongoing Phase 1a/1b to be presented at SITC -- Company will also present new ...

As of September 26, 2024, 33 CD19 CAR T-naïve patients with LBCL (median age, 66 years; median number of previous therapies, 3) received allogeneic CAR T cells. CAR T-cell expansion was observed ...

Atara Biotherapeutics is a biotech company developing allogeneic EBV T cells for oncology and autoimmune indications, with a world-first allogeneic T-cell approval in Europe and nearing FDA approval.

For years, the pancreas has been being taught in biology class as an easy system: insulin lowers blood sugar, and glucagon raises it. But that’s much too simple, new research says. Scientists at Duke ...